Neglected Diseases — Tuberculosis Technologies Available from NIH, Universities and Other Non-profit Organizations
JOHNS HOPKINS UNIVERSITY (JHU)
JHU 4332
Treatment of Persistent Bacterial Infections with Energy Inhibitors
JHU 1506
"whmd": Essential Cell Division Gene in Mycobacteria
JHU 1283
Identification of Pyrazinamide-Resistant Mycobacteria and Methods for Treating Mycobacterial Infections
NATIONAL INSTITUTES OF HEALTH (NIH)
E-286-2002
Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis
E-196-2002
Bromotyrosine-Derived Inhibitors of Mycothiol-S-Conjugate Amidase
E-296-2001
Alleviating Symptoms of Th2-Like Cytokine Mediated Disorders by Reducing IL-13 Receptor-Expressing Cells in the Respiratory Tract*
E-093-2000
Method of Diagnosing Multidrug Resistant Tuberculosis
E-238-1997
Novel Attenuated Strains of Mycobacterium tuberculosis
E-095-1994
Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
* Some technologies have multiple potential uses.
Overview
African Trypanosomiasis (Sleeping Sickness)
Dengue Fever
General (Vaccines and Biotherapeutics)
Hepatitis B
HIV/AIDS
Intestinal Parasites
Leprosy
Lymphatic Filariasis (Elephantiasis)
Malaria
Rotavirus
Schistosomiasis
Tuberculosis
Visceral Leishmaniasis
